Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025 [1][2]. - Allegations include that Vistagen provided misleading statements about the success of its Phase 3 PALISADE-3 trial for fasedienol while concealing adverse facts [2][3]. Group 2: Trial Results and Impact - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show statistically significant improvement on its primary endpoint, leading to a dramatic stock price drop from $4.36 to $0.86, a decline of over 80% [3]. Group 3: Next Steps for Investors - Shareholders wishing to serve as lead plaintiffs must submit their papers by March 16, 2026, but participation is not required to be eligible for recovery [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vistagen-therapeutics-inc-loss-submission-form/?id=183336&from=3 CLASS ...

NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/vistagen-therapeut ...

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a securities class action lawsuit due to alleged misleading statements regarding its clinical trial program for its lead drug candidate, with a lead plaintiff deadline set for March 16, 2026 [1][8]. Group 1: Allegations of Misleading Statements - Management allegedly created an overwhelmingly positive impression about the clinical trial program, emphasizing "notable enhancements" and "operational changes" intended to improve enrollment quality and limit variability [3]. - The company claimed that positive results from a prior Phase 3 trial, combined with operational improvements, positioned the subsequent study as a confirmatory trial with a strong likelihood of success [4]. Group 2: Omitted Risks - The complaint alleges that while promoting the trial's positive aspects, the company failed to disclose material risks inherent in the clinical trial design, specifically known issues with public speaking challenge endpoints that often show elevated placebo responses and site variability [5]. - Defendants are accused of continuing to promote the trial modifications and presenting the study as likely to succeed while concealing these known risks from investors [6].

Core Viewpoint - A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. alleging false and misleading statements regarding the risks associated with the Phase 3 PALISADE-3 trial of fasedienol [1] Group 1: Lawsuit Details - The lawsuit claims that Vistagen failed to disclose material adverse facts related to the risks of failure in its clinical trial [1] - The class action is aimed at shareholders who purchased Vistagen shares between April 1, 2024, and December 16, 2025, and suffered significant losses [2] Group 2: Legal Representation - Shareholders are encouraged to contact Holzer & Holzer, LLC for legal representation, a firm recognized for its work in securities litigation [3] - The deadline for shareholders to be appointed as lead plaintiff in the case is March 16, 2026 [3]

New York, New York--(Newsfile Corp. - February 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a con ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][7]. - The lead plaintiff must file a motion with the Court by March 16, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder [5]. - Defendants reportedly made overly positive statements about the drug's trial success while concealing adverse facts about the Phase 3 PALISADE-3 trial [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [2][5]. Group 1: Company Overview - Vistagen Therapeutics, Inc. is a company listed on NASDAQ under the ticker VTGN [2]. - The company is developing fasedienol, an investigational pherine candidate aimed at treating social anxiety disorder [5]. Group 2: Legal Investigation and Claims - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][7]. Group 3: Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, resulting in a significant stock price drop of $3.50, or 80.27%, closing at $0.86 [6].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [7]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact Bragar Eagel & Squire for further assistance [4].